NewsletterEdition 1: HHS's Peptide Policy, Retatrutide's Phase 3 Data and an FDA Warning Letter
Best Peptides Today, edition 1: HHS's interim peptide compounding policy, retatrutide's phase 3 results and an FDA warning letter on compounded GLP-1s.
BPC-157Compounded versions: not FDA-approved
TB-500Compounded versions: not FDA-approvedAnimal studies only
RetatrutideInvestigational
SemaglutideFDA-approvedCompounded versions: not FDA-approved
TirzepatideFDA-approvedCompounded versions: not FDA-approved